{"id":"W3088817799","doi":"10.1016/j.annonc.2020.08.419","title":"317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Ottawa Hospital; BC Cancer Agency; Sunnybrook Health Science Centre; McGill University; Jewish General Hospital; University of Alberta; Grand River Hospital","funders":"Medac; Eisai; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Neutropenia; Internal medicine; Breast cancer; Letrozole; Population; Febrile neutropenia; Interim analysis; Chemotherapy regimen; Progression-free survival; Cancer; Surgery; Chemotherapy; Clinical trial; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002482086,0.0001821431,0.0005712238,0.00004728074,0.0001461462,0.000006948645,0.0003048729,0.0001345275,0.0002966952],"category_scores_gemma":[0.000196514,0.0001201505,0.0001583549,0.0003792869,0.0002806445,0.00009676727,0.0000602048,0.0002805948,0.000005785925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001962437,"about_ca_system_score_gemma":0.0008138465,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1384357,"about_ca_topic_score_gemma":0.1747598,"domain_scores_codex":[0.9981378,0.000223494,0.0006750256,0.0003067278,0.0003119849,0.0003449478],"domain_scores_gemma":[0.9982085,0.0001952325,0.0005977893,0.000425551,0.0003596087,0.0002133795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.3097376,0.001170187,0.01322373,0.00006457117,0.001297925,0.00003932669,0.005001053,0.001622518,0.04874802,0.0005084392,0.02613477,0.5924519],"study_design_scores_gemma":[0.2419236,0.005468337,0.2315746,0.0002834929,0.0004270122,0.0000269398,0.001089022,0.0007858807,0.03124801,0.000788422,0.4859271,0.0004576396],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8515085,0.0004425434,0.00001704446,0.1434788,0.0004326623,0.0009323431,0.002643726,0.00002368405,0.0005207416],"genre_scores_gemma":[0.9879077,0.00009117167,0.0001149944,0.01082758,0.0005517318,0.00004102668,0.000406486,0.00002542254,0.00003387023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5919942,"threshold_uncertainty_score":0.8673015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1034470489164256,"score_gpt":0.4071122338212833,"score_spread":0.3036651849048577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}